Authors


Nancy Holekamp, MD

Latest:

ACHIEVING IMPROVED OUTCOMES THROUGH PARTNERSHIPS BETWEEN OPTOMETRISTS AND RETINA SPECIALISTS

Considerations in the treatment of diabetic retinopathy and diabetic macular edema.


Marco Mura, MD

Latest:

Managing neovascular retinal disease in COVID-19 era requires careful approach

Minimizing clinic visits, maximizing use of imaging modalities are key.


Karl Stonecipher, MD

Latest:

Final Pearls on Managing Dry Eye Patients With Comorbidities

Ophthalmologists end their discussion on the management of dry eye disease with other ocular comorbidities highlighting key takeaways and prospective advances in care and outcomes.


Mark T. Dunbar, OD, FAAO

Latest:

ACHIEVING IMPROVED OUTCOMES THROUGH PARTNERSHIPS BETWEEN OPTOMETRISTS AND RETINA SPECIALISTS

Considerations in the treatment of diabetic retinopathy and diabetic macular edema.


Samir N. Patel, MD

Latest:

Focusing on postinjection endophthalmitis

Systemic immunosuppression may prevent devastating complication in patients.



Victor H. Gonzalez, MD

Latest:

Seize underutilized opportunity to treat glaucoma during vitrectomy

Ophthalmologists can reduce IOP and medications with endocyclophotocoagulation while in the eye.


Marta Ibarz Barberá, MD

Latest:

Benefits of topography-guided treatments for irregular corneas

Procedure can improve best-corrected visual acuity, enhancing quality of life for patients.



Carl D. Regillo, MD, FACS, FASRS

Latest:

Considerations for the Future of Biosimilars in the Treatment of Retinal Disorders

Carl D. Regillo, MD, and Jennifer I. Lim, MD, emphasize the high regulatory standards of equivalence and safety of biosimilars in considering the role they will play in the evolving treatment landscape for retinal disorders.


Dilraj S. Grewal, MD

Latest:

Weighing treatments for chronic postop cystoid macular edema

Prompt and adequate action is a key to facilitating the best recovery in patients.


Kassi Jackson

Latest:

FDA approves RYZUMVI (Phentolamine Ophthalmic Solution) for the treatment of pharmacologically-induced mydriasis

Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents.


Gary W. Jerkins, MD

Latest:

Increasing your practice’s reach, relevance, and revenue with clinical trials

Working as an investigator can prove to be a positive experience for physicians


Rahul T. Pandit, MD

Latest:

The eyes offer conjunctival clue to COVID-19

A patient's vision loss leads to another diagnosis


Neda Shamie, MD

Latest:

What’s Your WhEYE? A conversation with Paul Badawi, CEO of Sight Sciences

Paul Badawi, co-founder and CEO of Sight Sciences, sits down with host Neda Shamie, MD, to discuss his journey into the field of eye care, what motivates him, the transformative approach to glaucoma patient care, and the spark that led him and his ophthalmologist brother, David Badawi, MD, to start the company together.



Dilsher S. Dhoot, MD

Latest:

Patient case 2: DME Patient Treated with Ranibizumab Biosimilar

Dilsher S. Dhoot, MD discusses a recent case-based roundtable meeting on anti-VEGF biosimilars, highlighting the first of two case discussions.


A. Paul Chous, MA, OD, FAAO

Latest:

Future Directions of Retinal Eye Disorders

Dilsher S. Dhoot, MD, and A. Paul Chous, MA, OD, FAAO, discuss future directions and unmet needs in the field of retinal eye disease.


James G. Chelnis, MD

Latest:

Driving practice growth: Expand on link between dry eye, aesthetics

One obvious trend has been that dry eye disease is a concurrent problem for virtually all my patients, and we need to address it for optimum comfort and surgical results.


Dagny Zhu, MD

Latest:

Seasonal allergies: Common trigger for dry eye flares

Short-term steroid use can alleviate patient discomfort.



Howard D. Pomeranz, MD, PhD

Latest:

Protection of eyes during prone positioning must be routinely monitored in ICU

Treatment of patients with COVID-19 should include ophthalmic considerations.


Andrew G. Lee, MD

Latest:

VLOG: Neuro-Ophthalmology interprofessional eConsults

Andrew Lee, MD, Andrew Carey, MD, and Elizabeth Fortin, MD, sit down on this episode of the NeuroOp Guru to discuss neuro-ophthalmology, interprofessional eConsults, and whether they provide timely and valuable guidance


Jon Carter

Latest:

Optic Relief - 2023 Issues

The latest in Optic Relief from Ophthalmology Times




Julianne Mobilian

Latest:

Patient outcomes and intraoperative use of phenylephrine/ketorolac 1%/0.3%

ICYMI: Denise Visco, MD, shares the take-home message from her 2019 ASCRS presentation.


Melina I. Morkin, MD

Latest:

Neuropathic dry eye: When serum defeats tears

Ophthalmology Times is pleased to announce Melina I. Morkin, MD, and Pedram Hamrah, MD, FACS, of New England Eye Center/Tufts Medical Center, Department of Ophthalmology, Tufts University School of Medicine, Boston, as the third-place winner of the 2017 Resident Writer’s Award Program, sponsored by Allergan. Their entry is featured here.


Pedram Hamrah, MD, FACS

Latest:

Neuropathic dry eye: When serum defeats tears

Ophthalmology Times is pleased to announce Melina I. Morkin, MD, and Pedram Hamrah, MD, FACS, of New England Eye Center/Tufts Medical Center, Department of Ophthalmology, Tufts University School of Medicine, Boston, as the third-place winner of the 2017 Resident Writer’s Award Program, sponsored by Allergan. Their entry is featured here.


Alexander Nguyen, MD

Latest:

Cyclosporine for dry eye associated with anti-PD-1 therapy

Topical cyclosporine may be useful for treating dry eyes associated with immunomodulatory agents like nivolumab, which markedly upregulate T cell activation. In caring for patients with ocular side effects associated with cancer treatment, the delivery of proper ophthalmic care is critical.

© 2024 MJH Life Sciences

All rights reserved.